National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ciltacabtagene autoleucel (Carvykti®). HTA ID: 22021

Ciltacabtagene autoleucel (Carvykti®) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.



NCPE Assessment Process Complete
Rapid review commissioned 11/04/2022
Rapid review completed 12/05/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care.